Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1419807
This article is part of the Research Topic Immunobiology and Immunotherapeutics in Myelodysplastic Syndrome and Acute Myeloid Leukemia View all 5 articles

The Immunobiology of Myelodysplastic Neoplasms (MDS): A Mini-Review

Provisionally accepted
Shruthi Kannan Shruthi Kannan Rolando A. Vedia Rolando A. Vedia Jeffrey J. Molldrem Jeffrey J. Molldrem *
  • University of Texas MD Anderson Cancer Center, Houston, United States

The final, formatted version of the article will be published soon.

    This mini review summarizes the immunobiology of myelodysplastic syndromes, specifically focusing on the interactions between immune cells, cytokines, and dysplastic cells within the tumor microenvironment in the bone marrow. We elucidate in detail how immune dysregulation and evasion influence the initiation and progression of myelodysplastic syndromes, as well as resistance to therapy and progression to AML. In addition, we highlight a range of therapeutic strategies, including the most recent breakthroughs and experimental therapies for treating MDS. Finally, we address the existing knowledge gaps in the understanding of the immunobiology of MDS and propose future research directions, promising advancements toward enhancing clinical outcomes and survival for patients with MDS.

    Keywords: Myelodysplastic neoplasms, Myelodysplastic Syndromes, immune dysfunction, Immunomodulatory therapies, immunobiology

    Received: 18 Apr 2024; Accepted: 27 Aug 2024.

    Copyright: © 2024 Kannan, Vedia and Molldrem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jeffrey J. Molldrem, University of Texas MD Anderson Cancer Center, Houston, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.